# **IMPACT OF IMPLEMENTING A GLOBAL COLLABORATIVE PHYSICIAN-PHARMACIST STRATEGY ON PROPHYLACTIC ANTIBIOTIC PRACTICES IN A UNIVERSITY HOSPITAL CENTER**

<u>A. Pardo<sup>1,2</sup></u>, R. Demeester<sup>3</sup>, M. Rivolta<sup>4</sup>, M. Joris<sup>5</sup>, S. Sténuit<sup>1</sup>

<sup>1</sup>Marie Curie Civil Hospital – CHU Charleroi, Pharmacy, Charleroi, Belgium

<sup>2</sup>University of Mons, Laboratory of Therapeutic Chemistry and Pharmacognosy, Mons, Belgium

<sup>3</sup>Marie Curie Civil Hospital – CHU Charleroi, Infectious Diseases, Charleroi, Belgium

<sub>4</sub>University of Mons, Mathematics, Mons, Belgium

<sup>5</sup>Marie Curie Civil Hospital – CHU Charleroi, Cardiothoracic Surgery, Charleroi, Belgium

Antibiotic prophylaxis is substantially important to prevent surgical site infections (SSIs). Surgical antibiotic prophylaxis (SAP) is an important quality criteria integrated in the 2014-2019 strategic plan of the Belgian Antibiotic Policy Coordination Committee (BAPCOC) (1). The risk of SSIs is cut in half when SAP is compliant with recommendations (2). To evaluate this compliance, several criteria for SAP prescriptions can be observed: the indication, the antibiotic molecule, the antibiotic dose, the route of administration, the timing, the number of administrations, the duration of the prophylaxis, any additional administrations. According to previous published papers, surgical antibiotic prophylaxis (SAP) practices could be optimized by the implementation of a persuasive strategy (3, 4, 5).



A) To identify risk factors associated with non-compliance towards prophylactic antibiotic guidelines

B) To test the impact of a combined intervention strategy on compliance towards prophylactic antibiotic guidelines



Interventions performed in the operating area between January 11, 2016 and April 22, 2016 (obtained through computer extraction)

C.H.U. de Charleroi

ND

80

S ш

OBJEC

DS

METHO

## **Inclusion criteria\***

Patients > 18 years old Patients who had one of the following 5 interventions: total hip prosthesis, coronary artery bypass grafting, colorectal surgery, transurethral resection of the prostate and endoscopic retrograde cholangiopancreatography

## **Exclusion criteria**\*\*

Patients < 18 years old Patients with a documented infection at the time of the intervention

Data collection and analysis for included interventions

Pre-test group

A) Risk factors of non-compliance in the pre-test group?

#### **Retrospective observational transversal study**

 $\rightarrow$  using a multivariate statistical analysis (Logistic regression models and Wald Tests)  $\rightarrow$  with Odds Ratios (ORs) determination for the relationships between each independent variable and the outcome variables :

**INDEPENDENT VARIABLES** 

**OUTCOME VARIABLES** 





**Compilation and** 

diffusion of Guidelines

Data collection and analysis Test group

**B)** Impact of the combined intervention strategy on compliance towards prophylactic antibiotic guidelines ?

Interventions performed in the operating

area between January 9, 2017 and April 21, 2017

(obtained on the basis of the presence of

pharmaceutical interventions)

1) Similarity between the pre-test group and the test group

 χ2 test for categorical variables (gender, number of patients per type of intervention, number of long duration interventions (> 3 hours), number of patients who received prophylactic antibiotics)

 Student's t-test for the age variable

• χ2 test comparing the % of compliance between the two

Encoding of an antibiotic prophylaxis recommendation based on patient parameters  $\Rightarrow$ accessible in patients' computerized records . . . •

**Preoperative pharmaceutical** 

interventions to practitioners if :

presence of inclusion criteria\*

absence of exclusion criteria \*\*



| <ul> <li>Age</li> <li>Obesity</li> <li>Gender</li> <li>IgE Mediated Penicillin (or Ciprofloxacin)<br/>Allergy</li> <li>Multidrug-resistant organisms</li> <li>American Society of Anaesthesiologists Score<br/>&gt; 2</li> <li>Length of Preoperative Stay</li> <li>Type of Intervention</li> <li>Surgeon or Gastroenterologist</li> <li>Anesthetist</li> <li>Presence of a nurse anesthetist during the<br/>intervention</li> <li>Duration of the intervention</li> <li>Blood loss during surgery ≥ 1,5L</li> </ul> | Compliance in terms of 11 iter<br>• Indication<br>• Molecule(s)<br>• Dose(s)<br>• Route of administration<br>• Time of administration(s)<br>• Number of administration(s)<br>• Duration of prophylaxis<br>• Additional molecule(s)<br>• Additional Dose(s)<br>• Route of administration for Add<br>molecule(s)<br>• Time of additional administration | itional<br>on(s) | <complex-block><complex-block></complex-block></complex-block>                                                                                                                                                                                              | 2) Differe<br>compliance be<br>pre-test grou<br>test gr<br>? | ance of<br>etween the<br>p and the<br>oup | ups for each of<br>ns audited and<br>ns together | the 11<br>for the 11 |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------------------------------------------|--------------------------------------------------|----------------------|--|
| A) Identification of non-compliance risk factors<br>in the pre-test group                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                       |                  | B.1) General characteristics of patients in the pre-test group and the test group<br>→ Similarity between the two groups in terms of clinical and demographic characteristics<br>(p> 0.05 except for the number of transurethral resection of the prostate) |                                                              |                                           |                                                  |                      |  |
| Risk factor of non<br>Compliance <sup>(i)</sup> Compliance                                                                                                                                                                                                                                                                                                                                                                                                                                                           | e item impacted Z-test P                                                                                                                                                                                                                                                                                                                              | OR<br>(95% IC)   | Characteristics                                                                                                                                                                                                                                             | Pre-test                                                     | Test                                      | Total                                            | <b>b</b> (9)         |  |

|                                            | Indication -2,383 0,01                                |        | 0,0172   | 0,0345<br>(0,0022-0,5502) |
|--------------------------------------------|-------------------------------------------------------|--------|----------|---------------------------|
| IgE Mediated Penicillin (or                | Molecule(s)                                           | -2,012 | 0,0442   | 0,1282<br>(0,0173-0,9481) |
| Ciprofloxacin) Allergy                     | Additional molecule(s)                                | -1,966 | 0,0493   | 0,0840<br>(0,0071-0,9924) |
| Duration of the intervention<br>(HH:mm:ss) | Time of additional administration(s)                  | -5,028 | 4,96E-07 | 0,5042<br>(0,3861-0,6585) |
|                                            | Molecule(s)                                           | -3,233 | 0,0012   | 0,0187<br>(0,0017-0,2086) |
|                                            | Dose(s)                                               | -3,321 | 0,0009   | 0,0623<br>(0,0194-0,2007) |
| Colorectal surgery                         | Additional molecule(s)                                | -5,346 | 8,98E-08 | 0,0114<br>(0,0022-0,0588) |
|                                            | Additional Dose(s)                                    | -4,365 | 1,27E-05 | 0,0479<br>(0,0122-0,1875) |
|                                            | Route of administration for<br>Additional molecule(s) | -4,924 | 8,50E-07 | 0,0133<br>(0,0024-0,0743) |
|                                            | Time of additional administration(s)                  | -2,06  | 0,0394   | 0,2354<br>(0,0594-0,9323) |
|                                            | Molecule(s)                                           | -3,07  | 0,021    | 0,0933<br>(0,0205-0,4243) |
|                                            |                                                       |        |          | 0 161/                    |

| Characteristics                                                                        | Pre-test                 | Test        | Total       | <b>b</b> (9)       |
|----------------------------------------------------------------------------------------|--------------------------|-------------|-------------|--------------------|
| Number of Interventions, n                                                             | 130                      | 118         | 248         |                    |
| Female, n (%)                                                                          | 48 (36,92)               | 49 (41,53)  | 97 (39,1)   | 0,46 <sup>NS</sup> |
| Age (yr), mean±SD                                                                      | 66,32 ± 11,68            | 68,36±13,75 | 67,29±12,73 | 0,21 <sup>NS</sup> |
| Transurethral resection of the prostate, n (%)                                         | 26 (20)                  | 11 (9,32)   | 37 (14,92)  | 0,02*              |
| Coronary artery bypass grafting, n (%)                                                 | 38 (29,23)               | 34 (28,81)  | 72 (29,03)  | 0,94 <sup>NS</sup> |
| Colorectal surgery, n (%)                                                              | 17 (13,08)               | 22 (18,64)  | 39 (15,73)  | 0,23 <sup>NS</sup> |
| Total hip prosthesis, n (%)                                                            | 30 (23,08)               | 34 (28,81)  | 64 (25,81)  | 0,30 <sup>NS</sup> |
| Endoscopic retrograde cholangiopancreatography, n (%)                                  | 19 (14,62)               | 17 (14,41)  | 36 (14,52)  | 0,96 <sup>NS</sup> |
| Duration of intervention > 3h, n (%)                                                   | 48 (36,92)               | 52 (44,07)  | 100 (40,32) | 0,25 <sup>NS</sup> |
| Number of interventions for which prophylactic<br>antibiotics were administered, n (%) | 113 (86,92)              | 109 (92,37) | 222 (89,52) | 0,16 <sup>NS</sup> |
| Comparing the pretect group with the test group: NS_pot si                             | ignificant: *significant |             |             |                    |

Comparing the pretest group with the test group. No, not significant, significant

B.2) Comparison of antibiotic prophylaxis practices in the pre-test group (n = 130) versus the test group (n = 118)

 $\rightarrow$  Improved compliance for all items assessed (test group vs. pre-test group)

Missing data

(P < 0.05 for all items assessed)

|                                            |                                                       |        |          | (0,0433-0,3724)           |
|--------------------------------------------|-------------------------------------------------------|--------|----------|---------------------------|
| Transurethral resection of<br>the prostate | Route of administration                               | -4,44  | 2,37E-09 | 0,0393<br>(0,0094-0,1641) |
|                                            | Time of administration                                | -6,093 | 1,33E-09 | 0,0293<br>(0,0094-0,0918) |
|                                            | Route of administration for<br>Additional molecule(s) | -3,487 | 0,0005   | 0,0549<br>(0,0107-0,2805) |
| Total hip prosthesis                       | Duration of prophylaxis                               | -5,002 | 5,66E-07 | 0,0602<br>(0,0200-0,1811) |
|                                            |                                                       |        |          |                           |

Dose(s)

<sup>(1)</sup>Some anesthetists and surgeons have also emerged as risk factors of non-compliance. However, we cannot exclude a dependence between independent variables (cf. link between practitioners and certain types of intervention).

 $\Rightarrow$ These findings are consistent with those described in the literature

that also revealed as risk factors of non-compliance: allergy to

β-lactams and certain types of surgery as urological surgery and

 $\Rightarrow$ Lack of education and incomplete professional rules were probably

 $\Rightarrow$ The results of this observational study indicated that it was

necessary to implement improvement actions of practices.

the main barriers associated with the risk factors identified in the

digestive surgery (6).

pre-test group.

S

CONCLUSION

Test Test Test Test Test Pre-test Test Test Pre-test Test Pre-test Test Pre-test Pre-test Test Pre-test Pre-test Pre-test Indication Molecule(s) Dose(s) ime of administration Number of Duration of Additional molecule(s) Route of administration administration( prophylaxis administration(s)

 $\Rightarrow$ This positive impact revealed a culture change, an interest and an awareness observed within the practitioner's teams

This study shows that optimization of SAP practices is achievable within a proactive multidisciplinary approach.

The results presented in this work could be exploited as part of the the Deming Cycle for Continuous Quality Improvement. Following the assessment made in the pre-test group with identification of non-compliance risk factors, a combination of interventions was planned (Plan) and performed (Do). In the test group, including 118 interventions carried out in the operating area, a large number of scenarios appeared. These cases covered, for the most part, the various antibiotic prophylaxis regimens which have been greatly respected by the practitioners in the operating area (Check). Therefore, the plan implemented in this work, as well as the number of interventions and patients included in the study, allowed exploiting the quantitative and qualitative information observed to extend the guidelines implementation to other types of surgery and to plan new actions implemented is the development of a SAP prescription assistance software available for surgeons and anesthetists (<u>https://db.serv-idb.net/antibioproph</u>).

Repetition of active interventions and audits as well as analysis of clinical outcomes, antimicrobial resistance and nosocomial infections are interesting avenues for continuing the work.

### REFERENCES

1) Balligand E, Costers M, Van Gastel E. Belgian Antibiotic Policy Coordination Committee - Note de politique pour la législature 2014-2019. BAPCOC. 2014.

2) SFAR. Antibioprophylaxie en chirurgie et médecine interventionnelle (patients adultes). Actualisation 2010. Annales Françaises d'Anesthésie et de Réanimation. 2011;30:168–90.

3) Zhou L, Ma J, Gao J, Chen S, Bao J. Optimizing Prophylactic Antibiotic Practice for Cardiothoracic Surgery by Pharmacists' Effects. Medicine (Baltimore). 2016;95(9):e2753.

4) Prado MAMB, Lima MPJS, Gomes IdRH, Bergsten-Mendes G. The implementation of a surgical antibiotic prophylaxis program: The pivotal contribution of the hospital pharmacy. Am J Infect Control. 2002;30(1):49-56.

5) Fayolle-Pivot L, Weyb P-F, Petitjeans F, Puidupin M, Allaouchiche B, Escarment J. Contribution of information technologies to assess and improve professional practice: Example of management of surgical antibiotic prophylaxis. A nales Françaises d'Anesthésie et de Réanimation. 2013;32:241–5.

6) Muller A, Leroy J, Henon T, Patry I, Samain E, Chirouze C, et al. Surgical antibiotic prophylaxis compliance in a university hospital. Anaesthesia, Critical Care & Pain Medicine. 2015;34:289–94.



4-4CPS-069